AQST Quote, Financials, Valuation and Earnings

Akero Therapeutics, Inc. has a net margin of -120.61% compared to Aquestive Therapeutics, Inc.'s net margin of --. Aquestive Therapeutics, Inc.'s return on equity of -- beat Akero Therapeutics, Inc.'s return on equity of -32.14%.

Aquestive Therapeutics, Inc. has a consensus price target of $10.30, signalling upside risk potential of 59.94%. On the other hand Akero Therapeutics, Inc. has an analysts' consensus of $56.00 which suggests that it could grow by 2.51%. Given that Aquestive Therapeutics, Inc. has higher upside potential than Akero Therapeutics, Inc., analysts believe Aquestive Therapeutics, Inc. is more attractive than Akero Therapeutics, Inc..

Aquestive Therapeutics, Inc. has a beta of 1.590, which suggesting that the stock is 59.015% more volatile than S&P 500. In comparison Akero Therapeutics, Inc. has a beta of -0.399, suggesting its less volatile than the S&P 500 by 139.855%.

Aquestive Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akero Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aquestive Therapeutics, Inc. pays -- of its earnings as a dividend. Akero Therapeutics, Inc. pays out -- of its earnings as a dividend.

Aquestive Therapeutics, Inc. quarterly revenues are $12.8M, which are larger than Akero Therapeutics, Inc. quarterly revenues of --. Aquestive Therapeutics, Inc.'s net income of -$15.4M is higher than Akero Therapeutics, Inc.'s net income of -$81.6M. Notably, Aquestive Therapeutics, Inc.'s price-to-earnings ratio is -- while Akero Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aquestive Therapeutics, Inc. is 14.71x versus -- for Akero Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -120.61% compared to Aquestive Therapeutics, Inc.'s net margin of 31.72%. Aquestive Therapeutics, Inc.'s return on equity of -- beat Eli Lilly & Co.'s return on equity of 106.26%.

Aquestive Therapeutics, Inc. has a consensus price target of $10.30, signalling upside risk potential of 59.94%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,045.59 which suggests that it could grow by 1.16%. Given that Aquestive Therapeutics, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Aquestive Therapeutics, Inc. is more attractive than Eli Lilly & Co..

Aquestive Therapeutics, Inc. has a beta of 1.590, which suggesting that the stock is 59.015% more volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.

Aquestive Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.58% to investors and pays a quarterly dividend of $1.50 per share. Aquestive Therapeutics, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Aquestive Therapeutics, Inc. quarterly revenues are $12.8M, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Aquestive Therapeutics, Inc.'s net income of -$15.4M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Aquestive Therapeutics, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 51.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aquestive Therapeutics, Inc. is 14.71x versus 15.86x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Madrigal Pharmaceuticals, Inc. has a net margin of -120.61% compared to Aquestive Therapeutics, Inc.'s net margin of -39.75%. Aquestive Therapeutics, Inc.'s return on equity of -- beat Madrigal Pharmaceuticals, Inc.'s return on equity of -40.56%.

Aquestive Therapeutics, Inc. has a consensus price target of $10.30, signalling upside risk potential of 59.94%. On the other hand Madrigal Pharmaceuticals, Inc. has an analysts' consensus of $563.80 which suggests that it could fall by -2.78%. Given that Aquestive Therapeutics, Inc. has higher upside potential than Madrigal Pharmaceuticals, Inc., analysts believe Aquestive Therapeutics, Inc. is more attractive than Madrigal Pharmaceuticals, Inc..

Aquestive Therapeutics, Inc. has a beta of 1.590, which suggesting that the stock is 59.015% more volatile than S&P 500. In comparison Madrigal Pharmaceuticals, Inc. has a beta of -1.034, suggesting its less volatile than the S&P 500 by 203.399%.

Aquestive Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aquestive Therapeutics, Inc. pays -- of its earnings as a dividend. Madrigal Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Aquestive Therapeutics, Inc. quarterly revenues are $12.8M, which are smaller than Madrigal Pharmaceuticals, Inc. quarterly revenues of $287.3M. Aquestive Therapeutics, Inc.'s net income of -$15.4M is higher than Madrigal Pharmaceuticals, Inc.'s net income of -$114.2M. Notably, Aquestive Therapeutics, Inc.'s price-to-earnings ratio is -- while Madrigal Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aquestive Therapeutics, Inc. is 14.71x versus 17.36x for Madrigal Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

TransCode Therapeutics, Inc. has a net margin of -120.61% compared to Aquestive Therapeutics, Inc.'s net margin of --. Aquestive Therapeutics, Inc.'s return on equity of -- beat TransCode Therapeutics, Inc.'s return on equity of -775.26%.

Aquestive Therapeutics, Inc. has a consensus price target of $10.30, signalling upside risk potential of 59.94%. On the other hand TransCode Therapeutics, Inc. has an analysts' consensus of $10.00 which suggests that it could grow by 3229.37%. Given that TransCode Therapeutics, Inc. has higher upside potential than Aquestive Therapeutics, Inc., analysts believe TransCode Therapeutics, Inc. is more attractive than Aquestive Therapeutics, Inc..

Aquestive Therapeutics, Inc. has a beta of 1.590, which suggesting that the stock is 59.015% more volatile than S&P 500. In comparison TransCode Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Aquestive Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. TransCode Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Aquestive Therapeutics, Inc. pays -- of its earnings as a dividend. TransCode Therapeutics, Inc. pays out -- of its earnings as a dividend.

Aquestive Therapeutics, Inc. quarterly revenues are $12.8M, which are larger than TransCode Therapeutics, Inc. quarterly revenues of --. Aquestive Therapeutics, Inc.'s net income of -$15.4M is lower than TransCode Therapeutics, Inc.'s net income of -$4.9M. Notably, Aquestive Therapeutics, Inc.'s price-to-earnings ratio is -- while TransCode Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Aquestive Therapeutics, Inc. is 14.71x versus -- for TransCode Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.